antigen

vaccine dose

vaccination route

macaque species

challenge virus

challenge route

viremia/ total

disease/ total

survival/ total

reference

ZEBOV-GP

1x 107 pfu

I.M

cynomolgus

ZEBOV

I.M

0/4

0/4

4/4

[25]

MARV-GP

5x 107 pfu

I.M

cynomolgus

MARV Musoke

I.M

0/4

0/4

4/4

[25]

MARV-GP

2x 107 pfu

I.M

cynomolgus

MARV Angola

I.M

0/3

0/3

3/3

[28]

MARV-GP

2x 107 pfu

I.M

cynomolgus

MARV Ravn

I.M

0/3

0/3

3/3

[28]

MARV-GP

2x 107 pfu

I.M

cynomolgus

MARV Musoke

I.M

0/1

0/1

1/1

[28]

ZEBOV-GP

2x 107 pfu

I.M

cynomolgus

ZEBOV

AEROSOL

0/3

0/3

3/3

[26]

MARV-GP

2x 107 pfu

I.M

cynomolgus

MARV Musoke

AEROSOL

0/4

0/4

4/4

[26]

ZEBOV-GP

2x 107 pfu

I.N

cynomolgus

ZEBOV

I.M

n.a.

0/4

4/4

[27]

ZEBOV-GP

2x 107 pfu

ORAL

cynomolgus

ZEBOV

I.M

n.a

0/4

4/4

[27]

ZEBOV-GP

2x 107 pfu

I.M

cynomolgus

ZEBOV

I.M

n.a.

0/2

2/2

[27]

ZEBOV-GP SEBOV-GP MARV-GP

1x 107 pfu each

I.M

cynomolgus

ZEBOV

I.M

0/3

0/3

3/3

[29]

ZEBOV-GP SEBOV-GP MARV-GP

1x 107 pfu each

I.M

cynomolgus

SEBOV

I.M

0/2

0/2

2/2

[29]

ZEBOV-GP SEBOV-GP MARV-GP

1x 107 pfu each

I.M

cynomolgus

CIEBOV

I.M

0/3

0/3

3/3

[29]

ZEBOV-GP SEBOV-GP MARV-GP

1x 107 pfu each

I.M

cynomolgus

MARV

Musoke

I.M

0/3

0/3

3/3

[29]

ZEBOV-GP

3x 107 pfu

I.M

cynomolgus

SEBOV

I.M

1/1

1/1

0/1

[29]

SEBOV-GP ZEBOV-GP MARV-GP

1x 107 pfu each

I.M

rhesus

SEBOV

I.M

0/3

0/3

3/3

[29]

ZEBOV-GP

2x 107 pfu

I.M

cynomolgus

BEBOV

I.M

4/4

4/4

3/4

[30]

CIEBOV-GP

2x 107 pfu

I.M

cynomolgus

BEBOV

I.M

3/3

3/3

1/3

[30]

N.D. = not determined
Table 2: Prseventive filovirus rVSV vaccination studies in NHPs.